# Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

> **NCT03019588** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 94 (actual)

## Conditions studied

- Gastric Neoplasms
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03019588
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-16
- **Primary completion:** 2021-06-29
- **Final completion:** 2021-06-29
- **Target enrollment:** 94 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2023-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03019588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03019588, "Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03019588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*